Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Hematologic Neoplasms 3Neoplasms, Plasma Cell 2Lymphoma 2Leukemia 2Infections 2Waldenstrom Macroglobulinemia 1Urinary Tract Infections 1Staphylococcal Infections 1Spasm 1Sleep Initiation and Maintenance Disorders 1Sepsis 1Seizures 1Schizophrenia, Treatment-Resistant 1Schizophrenia 1Retinitis 1Renal Insufficiency, Chronic 1Recurrence 1Pulmonary Arterial Hypertension 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pneumonia 1Pancreatic Neoplasms 1Pancreatic Diseases 1Pain 1Other Infectious Diseases 1Neutropenia 1Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Migraine Disorders 1

Interventions

chlorhexidine gluconate 1Probenecid 1Piperacillin, Tazobactam Drug Combination 1Levofloxacin 1Chlorhexidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bacterial Infections × Piperacillin, Tazobactam Drug Combination × Clear all
NCT00167999 2007-03-15

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
200 enrolled

Bacterial Infections, Escherichia coli Infections, Klebsiella Infections, Gram-Positive Bacterial Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡